Navigation Links
New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
Date:3/14/2010

devices portfolio, including products for coronary artery disease, vessel closure, endovascular disease, and structural heart disease.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

(1) In the EVEREST II trial, the primary safety endpoint is defined as major adverse events at 30 days, and the primary effectiveness endpoint is defined as freedom from death, surgery for valve dysfunction and mode
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Study Demonstrates Safety of Balloon Sinuplasty(TM) Technology in Pediatric Patients Suffering From Chronic Sinusitis
2. Tobiras Next-Generation Once-Daily CCR5 Receptor Antagonist Demonstrates Efficacy, Safety and Tolerability in Treatment-Experienced Patients With HIV
3. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
4. AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs
5. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
6. Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer
7. ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers
8. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
9. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
10. Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
11. European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... PLYMOUTH MEETING, Pa. , Sept. 22, 2014 ... ) announced today it has initiated a phase ... The trial will evaluate the safety, tolerability, and ... type 6 (HPV-6), which causes most aerodigestive cancers. ... tongue, nose, throat, vocal cords, and parts of ...
(Date:9/22/2014)... and NEW YORK , Sept. ... ACCP), has signed an exclusive, global license agreement ... and commercialization of its proprietary plasma fractionation process. ... team and its intention to strategically refocus and ... its plans to pursue a national listing for ...
(Date:9/22/2014)... Pa. , Sept. 22, 2014 ... a specialty biopharmaceutical company, today announced that its ... unsolicited, non-binding and conditional proposal from Endo International ... financial and legal advisors, has unanimously determined it ... of its existing merger agreement with QLT Inc. ...
Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
... SAN DIEGO, Feb. 6, 2012 Amylin Pharmaceuticals, Inc. (Nasdaq: ... quarter and year ended December 31, 2011. ... $164.9 million, which included net product sales of $160.9 million. ... 2011 was $17.6 million, compared to a non-GAAP operating income ...
... Feb. 6, 2012  Genomic Health, Inc. (Nasdaq: GHDX ... with the goal of improving the quality of diagnosis, communication ... with common and rare genetic conditions.   The subsidiary is expected ... first commercial service in 2013.  The new venture will be ...
Cached Medicine Technology:Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 2Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 3Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 4Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 5Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 6Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 7Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 8Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 9Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 ... whom all of the federal mesh lawsuits ( ... Corp. have been consolidated for pretrial matters, issued ... Scientific Corp. Pelvic Repair System Products Liability Litigation ... of West Virginia; Case no. 2:12-md-02326)—requiring that four ...
(Date:9/22/2014)... -- All sexually active women should be screened ... infections: chlamydia and gonorrhea, according to new recommendations ... The task force noted this recommendation includes ... age and pregnant women. Most women with ... a result, many infections go undetected. If left ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... are urging that all children aged 6 months and older ... Academy of Pediatrics updated their influenza vaccine recommendations to advise ... vaccine to build immunity. The AAP also wants parents of ... the nasal spray vaccine instead of the flu shot if ...
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) McMaster scientists have ... a new class of antibiotics. , Although dozens ... looked at how a certain part of bacteria are ... stopping it. , The discovery is important as ... is making the cures for infections ineffective. The World ...
(Date:9/22/2014)... September 22, 2014 Quincy Bioscience, ... United States, promotes National Self-Improvement Month ... all individuals should have access to self-improvement resources, ... , The demand for products that preserve health ... ever before. For over six years, Quincy Bioscience ...
Breaking Medicine News(10 mins):Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:Screen Women for Chlamydia, Gonorrhea, Experts Say 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:Quincy Bioscience Promotes National Self-Improvement Month 2
... Dramatically Cut Largest Source of Deadly Diesel Pollution in State ... 12 The California Air Resources Board today approved two ... of diesel pollution in the state and are the first ... Defense Fund (EDF). The Air Resource Board estimates that the ...
... national partners in effort to raise $5 million , ... National partners from the 17th annual Halloween Promotion benefiting ... celebrate raising more than $2.4 million to help the hospital ... , Companies represented at today,s recognition ceremony ...
... cells may make them more resilient during real attack, experts ... have long known that the creation of a "mini ... flow to arteries -- can actually reduce the damage from ... how that protective effect occurs, according to research from the ...
... PartsSource, the nation,s leading,supplier of replacement medical repair parts for ... in Ohio by the Case Western Reserve,University Weatherhead ... placed 14th on this year,s list with a growth rate ... eligible. , "The Weatherhead ...
... to bad treatment decisions, study shows , , FRIDAY, ... receive about the risk of their breast cancer ... whether to get chemotherapy more difficult, a new ... patients a bar chart, based on a standard ...
... A new report from the Institute of Medicine, THE ... ADMINISTRATION, examines why a commitment to global health is ... light of the current economic situation. The report ... goals the incoming administration should strive to meet, and ...
Cached Medicine News:Health News:California Rules to Cut Diesel Truck Pollution Called Most Sweeping in U.S. 2Health News:More Than $2.4 Million Raised by National Halloween Promotion Partners to Help St. Jude Fight Childhood Cancer 2Health News:Research Explains Benefit of 'Mini Heart Attack' 2Health News:Risk Info for Breast Cancer Patients Too Confusing 2
... with a curvature of 12 ... of the retina. Instrument shaft ... For cutting membranes adherent to ... for cutting in small folds ...
Claes Shielded Retinotomy Scissors, Curved Vertical...
Claes Shielded Retinotomy Scissors, Vertical...
Indirect hemagglutination assay (IHA) for the detection and semi-quantitation of human antibodies to the bacteria of the genus Leptospira. Each kit contains test cells, control cells, and positive an...
Medicine Products: